Zhou, Yinghui <br/><br/>
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.  [electronic resource] 

 -  Nature biotechnology  Jan 2010 
 - 71-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1546-1696 
<br/><br/><label>Standard No.: </label>10.1038/nbt.1595  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--metabolism<br/>Animals<br/>Chimera--metabolism<br/>Disease Models, Animal<br/>Embryonic Stem Cells--drug effects<br/>ErbB Receptors--metabolism<br/>Lung Neoplasms--metabolism<br/>Mice<br/>Mice, Transgenic<br/>Mutation--genetics<br/>Phenotype<br/>Piperazines--pharmacology<br/>Proto-Oncogene Proteins p21(ras)--metabolism<br/>Quinazolines--pharmacology<br/>Respiratory Insufficiency--metabolism<br/>Signal Transduction--drug effects